# Bristol-Myers Squibb

Type: Company (BMY)

Source: GetYourBrief — https://getyourbrief.com/entity/bristol-myers-squibb-company
Canonical HTML page: https://getyourbrief.com/entity/bristol-myers-squibb-company

## Recent coverage (2 stories, network-wide)

### JIA Market Set for 5.6% CAGR Growth Through 2036 as Biologics Drive Expansion
2026-02-19 02:08:55 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 4

The Juvenile Idiopathic Arthritis (JIA) market is projected to expand at a 5.6% CAGR through 2036, reaching multi-billion dollar valuations driven by advanced biologic therapies. Major pharmaceutical players including Bristol-Myers Squibb and Novartis are positioned to capture significant share with next-generation treatments.
Full story: https://getfinancebrief.com/story/juvenile-idiopathic-arthritis-market-growth-2036

### JIA Market to Reach $2.3B as Biologic Innovation Drives 5.6% CAGR through 2036
2026-02-19 02:07:52 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 4

The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.
Full story: https://getbiobrief.com/story/juvenile-idiopathic-arthritis-market-growth-2036

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.